11:15 AM
 | 
Oct 11, 2018
 |  BC Extra  |  Clinical News

FDA lifts hold on IND for CRISPR's sickle cell trial

CRISPR Therapeutics AG (NASDAQ:CRSP) and partner Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said late Wednesday that FDA lifted a clinical hold on an IND for a Phase I/II trial of gene therapy CTX001 to...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >